Your session is about to expire
← Back to Search
AB154 + AB122 for Glioblastoma
Study Summary
This trial is testing a new combination of drugs to treat glioblastoma, a type of brain cancer. The trial is divided into two groups, with the first group receiving the new combination of drugs to test for safety and the second group receiving the new combination of drugs as well as surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently being treated for an infection.My kidney function is within the normal range.I can carry out normal activities with minimal symptoms.I have not received a live vaccine within the last 30 days.My organs and bone marrow are functioning well.My neurosurgeon considers me a candidate for surgery to remove as much of the tumor as possible.I am not pregnant, will use birth control, and if male, will also use contraception during the study.My condition involves cancer in multiple locations.I have an active tuberculosis infection.I have been treated with bevacizumab.My cancer has come back once or twice after treatment, which included radiation.My blood clotting time is normal or near normal, or controlled if I'm on blood thinners.My diagnosis is Grade IV glioblastoma.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.My hemoglobin level is above 9 g/dL without needing transfusions or EPO.My neurosurgeon has approved me for surgery to remove as much of the tumor as possible.I have recovered from side effects of previous treatments, except for hair loss and tiredness.I need high doses of steroids to manage my condition.It's been 12 weeks since my last radiation, or I have confirmed tumor recurrence or new growth outside the treated area.I have another cancer besides skin or in situ cervical cancer that needs treatment.I have a history of or currently have non-infectious lung inflammation.I am 18 years old or older.I am currently or have previously been treated with drugs that boost the immune system.I have been diagnosed with an immunodeficiency condition, such as HIV/AIDS.I have active Hepatitis B or C.My blood clotting time is normal or near normal, even if I'm on blood thinners.It has been over 3 weeks or 5 half-lives since my last treatment before starting the study.
- Group 1: AB122 + AB154 Safety Cohort (Cohort A)
- Group 2: AB154 Surgical Cohort (Cohort B1)
- Group 3: AB122 Surgical Cohort (Cohort B2)
- Group 4: AB154 + AB122 Surgical Cohort (Cohort B3)
- Group 5: Placebo Surgical Cohort (Cohort B4)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree has the recruitment process for this clinical trial been successful?
"Affirmative. Information available on clinicaltrials.gov attests that this trial is actively seeking participants, which first appeared online on April 21st 2021 and was recently updated on July 5th 2022. At present, 46 patients are needed from one medical centre for enrolment in the study."
Are there any available vacancies in this clinical trial?
"Correct. The information hosted on clinicaltrials.gov shows that this medical trial, initially announced April 21st 2021, is actively enrolling patients. 46 participants are needed to be recruited from 1 distinct location."
Share this study with friends
Copy Link
Messenger